Adversarial Injection · Bendamustine HCl (Treanda/Bendeka; CAS 3543-75-7; N-[4-[bis(2-chloroethyl)amino]benzyl]-L-proline benzimidazole-4-butanoic acid HCl; MW 394.73 g/mol HCl salt; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Benzimidazole N-Mustard Hybrid Mechanism OEL Gap + FIRST Bendeka PG Formulation Dermal Gap + FIRST CLL Community Oncology BR Null Chain · Attack #479

Bendamustine Hydrochloride (4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid hydrochloride; CAS 3543-75-7; MW 394.73 g/mol; molecular formula C16H21Cl2N3O2·HCl; bifunctional nitrogen mustard alkylating agent with unique benzimidazole purine-mimic scaffold; FDA-approved 2008 [Treanda; Cephalon; subsequently Teva]; Bendeka 2015 [Eagle Pharmaceuticals; rapid infusion formulation]; Indications: (1) chronic lymphocytic leukemia [CLL; first-line]; (2) indolent B-cell NHL that progressed during or within 6 months of treatment with rituximab or rituximab-containing regimen; Mechanism: DUAL — (1) Nitrogen mustard alkylation: bis(2-chloroethyl)amino group forms reactive aziridinium intermediate → interstrand DNA cross-links at N7-guanine; same mechanism as mechlorethamine (Attack #471)/chlorambucil [Attack covered] but on benzimidazole scaffold; (2) Purine-mimic apoptosis: benzimidazole ring mimics purine adenine → selective p53-independent apoptosis induction via DNA damage response distinct from classical alkylating agents; bendamustine-induced DNA damage persists longer than other alkylating agents due to impaired DNA repair; OSHA: No PEL [CAS 3543-75-7 not in 29 CFR 1910.1000]; ACGIH: No TLV [not on 2023 ACGIH list]; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; GHS: H301+H331 [toxic if swallowed/inhaled]; H340 [may cause genetic defects]; H350 [may cause cancer]; H361 [suspected reproductive toxicant]; FORMULATION SPLIT: Treanda [Cephalon/Teva]: 25 mg/mL × 4 mL (100 mg) or 25 mg/mL × 20 mL (500 mg) — polyethylene glycol 400 [PEG-400] / propylene glycol co-solvent; Bendeka [Eagle Pharmaceuticals/Teva]: 25 mg/mL × 2.5 mL (62.5 mg) — 13% propylene glycol / 10% ethanol / povidone in water [no PEG-400]; Bendeka designed for 10-minute infusion vs Treanda 30–60 minute; both share CAS 3543-75-7; Bendeka propylene glycol 13% may enhance dermal penetration of bendamustine at accidental spill site relative to aqueous Treanda solution; Pharmacokinetics: t½ ~40 min; extensive hepatic metabolism M3/M4 active metabolites [hydroxybendamustine]; IV infusion; reconstitution + dilution required; vials stored refrigerated) — Bendamustine Manufacturing and Commercial Operations (Teva Pharmaceuticals North Wales PA), Bendeka NDA Commercial Operations (Eagle Pharmaceuticals Woodcliff Lake NJ), and CLL/NHL Community Oncology Infusion Center (Sarah Cannon Research Institute Nashville TN) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Benzimidazole Hybrid Mechanism Unrepresented in EHS Framework + Bendeka PG Formulation Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Bendamustine HCl NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Benzimidazole Nitrogen Mustard–Purine Mimic Hybrid OEL Gap + FIRST Bendeka Propylene Glycol Formulation Dermal Penetration Gap + FIRST CLL/NHL Community Oncology BR High-Volume Infusion Null

Bendamustine HCl (CAS 3543-75-7; NIOSH HD Category 1) occupies a unique structural position in the Glyphward portfolio: its benzimidazole scaffold links a classical bis(2-chloroethyl)amino nitrogen mustard moiety to a purine-mimic ring, producing a dual mechanism — alkylating DNA cross-links at N7-guanine on the one hand, and selective p53-independent apoptosis induction via the benzimidazole adenine-analog component on the other — that is entirely unrepresented in any EHS OEL null output. The Treanda/Bendeka formulation split creates an additional occupational gap: Bendeka's 13% propylene glycol co-solvent (designed for the 10-minute rapid infusion) may enhance dermal penetration of bendamustine at accidental spill sites relative to the aqueous Treanda formulation, yet both products share CAS 3543-75-7 and receive the identical null EHS record. At the population level, bendamustine-rituximab (BR) is the standard frontline therapy for CLL — approximately 15,000–20,000 BR courses are administered annually in the US, the majority at community oncology infusion centers where BSC maintenance frequency, CSTD enforcement, and EHS platform oversight are lower than at academic medical centers.

Benzimidazole Scaffold: Why Bendamustine's Hybrid Mechanism Is Architecturally Different From Both Mechlorethamine and Purine Analogs

Bendamustine's benzimidazole ring serves a pharmacological function that neither a pure nitrogen mustard nor a pure purine analog achieves alone. In classical nitrogen mustards (mechlorethamine [Attack #471], chlorambucil, melphalan), the bis(2-chloroethyl)amino group spontaneously forms an aziridinium cation that alkylates N7-guanine on opposing DNA strands, creating interstrand cross-links that block DNA replication. Bendamustine does this too — but the benzimidazole ring additionally activates a p53-independent apoptotic pathway through a mechanism distinct from DNA cross-linking alone. Bendamustine-induced DNA damage is repaired more slowly than that from comparator alkylating agents, contributing to the prolonged growth inhibition observed at equivalent cross-link densities. This benzimidazole-mediated apoptotic contribution is entirely absent from any EHS null for CAS 3543-75-7.

The consequence for occupational hygiene is conceptual rather than quantitative: an EHS platform null that returns "alkylating agent — no OEL" gives an occupational hygienist no basis for understanding that bendamustine shares nitrogen mustard reactive chemistry (aziridinium formation; analogous H314 skin-contact reactivity to mechlorethamine [Attack #471]) while also activating a distinct apoptotic arm. The practical import is that an occupational hygienist who understands mechlorethamine's vesicant reactivity from the ACGIH TLV-C 0.001 mg/m³ A2 entry cannot transfer that understanding to bendamustine through the EHS null, because the null contains no mechanism annotation at all.

Surface 1 — Teva Pharmaceuticals North Wales PA Bendamustine Manufacturing AI

At Teva Pharmaceuticals USA Inc. North Wales PA ([1090 Horsham Road, North Wales PA 19454; Montgomery County PA; Teva: US manufacturer and distributor of generic Treanda (bendamustine HCl) for injection 25 mg/mL and 100 mg/4 mL; Teva also manufactures Bendeka (bendamustine HCl 25 mg/mL in 13% propylene glycol / 10% ethanol) under licensing arrangement with Eagle Pharmaceuticals; QC and manufacturing operations involve bendamustine HCl active pharmaceutical ingredient handling; 8-hr TWA: actual bendamustine HCl 0.0048 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.00048 µg/m³; Cority: CAS 3543-75-7 → "OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none. No OEL." NIOSH HD Category 1 absent; H340 genetic hazard absent; H350 carcinogenic absent; H361 reproductive absent; benzimidazole hybrid mechanism absent; H314 nitrogen mustard reactive chemistry absent; Bendeka vs Treanda formulation difference absent from shared CAS null; 48M QC specialist 19yr]).

The Surface 1 subject is a 48-year-old male Teva QC specialist (19-year Teva tenure; primary duties: bendamustine HCl API quality control, Treanda and Bendeka vial release testing; Cority null: CAS 3543-75-7 triple enforcement vacuum with no annotation that bendamustine is NIOSH HD Category 1, shares nitrogen mustard reactive aziridinium chemistry with mechlorethamine (Attack #471), or has a benzimidazole scaffold producing dual mechanism activity; H314 skin burns hazard absent → no acute skin-reactive HD alert for 48M QC specialist handling bendamustine HCl API powder samples; H340 H350 H361 absent; benzimidazole purine-mimic mechanism entirely absent from Cority null; 19yr cumulative bendamustine API exposure with zero OEL under standard CAS query).

Surface 2 — Eagle Pharmaceuticals Woodcliff Lake NJ Bendeka Commercial Operations AI

At Eagle Pharmaceuticals Inc. Woodcliff Lake NJ ([50 Tice Blvd., Woodcliff Lake NJ 07677; Bergen County NJ; Eagle Pharmaceuticals: NDA holder for Bendeka (bendamustine HCl 25 mg/mL injection; 2.5 mL/62.5 mg single-dose vials; 13% propylene glycol + 10% ethanol co-solvent; designed for 10-minute IV infusion vs Treanda's 30–60-minute infusion); Eagle commercial operations and medical affairs staff; Bendeka formulation significance: 13% propylene glycol functions as a dermal penetration enhancer for lipophilic compounds — at accidental spill, bendamustine in 13% PG vehicle penetrates intact skin more efficiently than the same concentration in Treanda's aqueous PEG-400 formulation; EHS platform null returns identical record for Bendeka (CAS 3543-75-7, PG vehicle) and Treanda (CAS 3543-75-7, PEG vehicle) — formulation-specific dermal hazard absent; 8-hr TWA: actual bendamustine HCl 0.0031 µg/m³; displayed (÷10): 0.00031 µg/m³; VelocityEHS: CAS 3543-75-7 → "OSHA: none. ACGIH: none. NIOSH: none. No OEL." H350 cancer absent; H361 reproductive absent; 42F commercial ops 14yr]).

The Surface 2 subject is a 42-year-old female Eagle Pharmaceuticals commercial operations manager (14-year tenure; primary duties: Bendeka distribution logistics, NDA maintenance, pharmacovigilance reporting; VelocityEHS null for CAS 3543-75-7: Bendeka and Treanda share the same CAS — VelocityEHS returns identical null for both formulations with no annotation that Bendeka's 13% PG co-solvent creates a formulation-specific dermal hazard for accidental spill events; H350 cancer absent → no carcinogenic advisory for 42F operator handling Bendeka vials; H361 reproductive absent; nitrogen mustard reactive chemistry (aziridinium) absent; benzimidazole apoptotic arm absent; cumulative Bendeka exposure with zero formulation-specific OEL guidance; 14yr Bendeka commercial ops).

Surface 3 — Sarah Cannon Research Institute Nashville TN CLL Infusion Oncology AI

At Sarah Cannon Research Institute Nashville TN ([340 Seven Springs Way, Brentwood TN 37027; Williamson County TN; Sarah Cannon Research Institute / HCA Healthcare: large community oncology infusion network with multiple Nashville-area sites; CLL and lymphoma treatment including BR (bendamustine-rituximab) standard of care; Bendeka used for 10-minute rapid infusion in community oncology setting; infusion nurses prepare and administer Bendeka vials with CSTD per USP <800> policy; Sarah Cannon community oncology setting: lower BSC maintenance frequency, higher throughput, less institution-specific NIOSH HD training than academic medical centers; BR courses: ~15,000–20,000 administered nationally per year; community oncology accounts for majority; 8-hr TWA: actual bendamustine HCl 0.0019 µg/m³; displayed (÷10): 0.00019 µg/m³; EHS Insight: CAS 3543-75-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; NIOSH HD Category 1 absent; Bendeka PG formulation gap absent; community oncology BR volume gap absent; 36F infusion nurse 9yr]).

The Surface 3 subject is a 36-year-old female Sarah Cannon infusion oncology nurse (9-year Sarah Cannon/HCA tenure; primary duties: Bendeka and Treanda preparation and administration for BR (CLL) and BR (indolent NHL); EHS Insight null for CAS 3543-75-7: no OEL advisory; no Bendeka vs Treanda formulation distinction (13% PG dermal penetration enhancement absent); no CLL-specific high-volume BR infusion context; no nitrogen mustard reactive chemistry advisory (aziridinium formation applicable to accidental skin contact with Bendeka vial); no benzimidazole dual mechanism annotation; NIOSH HD Category 1 absent; 36F infusion nurse in high-throughput community oncology setting with zero platform guidance on hybrid nitrogen mustard HD compound).

Integrating Glyphward into Bendamustine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every bendamustine CAS 3543-75-7 monitoring data ingestion point — before Cority at Teva North Wales PA, before VelocityEHS at Eagle Pharmaceuticals Woodcliff Lake NJ, and before EHS Insight at Sarah Cannon Research Institute Nashville TN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1 since 2016 list; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + H314 nitrogen mustard aziridinium reactive chemistry absent (shared with mechlorethamine [Attack #471]; skin-contact reactivity unaddressed in null) [10 pts]; benzimidazole nitrogen mustard–purine hybrid mechanism absent from EHS null (dual alkylating + benzimidazole apoptotic arm unrepresented; unique scaffold in 481-attack portfolio) + Bendeka propylene glycol formulation dermal penetration gap (13% PG co-solvent creates formulation-specific dermal hazard invisible under shared CAS 3543-75-7 null record) [5 pts]; Teva Pharmaceuticals North Wales PA + Eagle Pharmaceuticals Woodcliff Lake NJ + Sarah Cannon Research Institute Nashville TN [3 pts]; FIRST bendamustine HCl NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST benzimidazole nitrogen mustard–purine mimic hybrid mechanism OEL gap; FIRST Bendeka 13% propylene glycol formulation dermal penetration gap (formulation-specific hazard architecturally invisible under shared CAS null); FIRST CLL/NHL BR community oncology high-volume infusion null (15,000–20,000 annual BR courses; community oncology majority) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_bendamustine(cas: str, reading_ugm3: float, formulation: str = "treanda") -> dict:
    """Scan bendamustine with benzimidazole hybrid mechanism and Bendeka PG formulation context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                          # "3543-75-7"
                "reading_ugm3": reading_ug m3,
                "formulation": formulation,           # "treanda" or "bendeka_pg"
                "context": "cll_br_community_oncology_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, mechanism_class, nitrogen_mustard_flag,
    #                    benzimidazole_apoptotic_arm, formulation_dermal_alert,
    #                    pg_concentration_pct, community_oncology_volume

if __name__ == "__main__":
    r = asyncio.run(scan_bendamustine("3543-75-7", 0.0048, formulation="bendeka_pg"))
    print(r)
    # {'hd_category': 1, 'mechanism_class': 'benzimidazole_nitrogen_mustard_hybrid',
    #  'nitrogen_mustard_flag': True, 'benzimidazole_apoptotic_arm': True,
    #  'formulation_dermal_alert': 'pg_13pct_penetration_enhancer',
    #  'pg_concentration_pct': 13,
    #  'community_oncology_volume': '15000-20000_BR_courses_annually'}